L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake

Yenisey, Çiğdem; ÜNAK, PERIHAN; ERTAY, Türkan; YÜREKLİ, Yakup; MÜFTÜLER BİBER, Fazilet Zümrüt; MEDİNE, Emin İlker

L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake

Yakup YÜREKLİ, (Adnan Menderes Üniversitesi, Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Aydın, Türkiye)

Perihan ÜNAK, (Ege Üniversitesi, Nükleer Bilimler Enstitüsü, Nükleer Uygulamalar Anabilim Dalı, İzmir, Türkiye)

Çiğdem YENİSEY, (Adnan Menderes Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, Aydın, Türkiye)

Türkan ERTAY, (Dokuz Eylül Üniversitesi, Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, İzmir, Türkiye)

Fazilet Zümrüt MÜFTÜLER BİBER, (Ege Üniversitesi, Nükleer Bilimler Enstitüsü, Nükleer Uygulamalar Anabilim Dalı, İzmir, Türkiye)

Emin İlker MEDİNE (Ege Üniversitesi, Nükleer Bilimler Enstitüsü, Nükleer Uygulamalar Anabilim Dalı, İzmir, Türkiye)

Molecular Imaging and Radionuclide Therapy

2 0

Yıl: 2011 Cilt: 20 Sayı: 1 Sayfa Aralığı: 1 - 6 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake

Öz:

Amaç: Bu çalışmanın amacı sisplatinin neden olduğu nefrotoksisiteye karşı L-karnitinin koruyucu etkisini ve bu etkiyi kantitatif renal Tc 99m DMSA uptake’ini kullanarak amifostinin etkisiyle karşılaştırmaktı. Gereç ve Yöntemler: Erkek Wistar sıçanlar her biri 6 hayvandan oluşan 6 gruba ayrıldı: 1) Kontrol grubu (serum fizyolojik, 5 ml/kg); 2) L-karnitin (CAR; 300 mg/kg intraperitoneal); 3)Amifostin (AMI; 200 mg /kg intraperitoneal); 4) Sisplatin (CIS; 7 mg/kg intraperitoneal); 5) Sisplatin artı L-karnitin (CIS + CAR); 6) Sisplatin artı amifostin (CIS + AMI). Grup 5 ve 6’da L-karnitin ve amifostin sisplatinden 30 dakika once enjekte edildi. İlaçlar verildikten sonraki 72. saatte kuyruk veninden 7.4 MBq/0.2 ml Tc 99m DMSA enjekte edildi.. Radyofarmasötiğin enjeksiyonundan 120 dakika sonra sıçanlar öldürüldü ve böbrekleri çıkarıldı. Enjekte edilen dozun her bir böbrek dokusu gramındaki oranı (%ID/g) hesaplandı. Böbrek fonksiyonu BUN ve plazma kreatinin düzeyi ölçümü ile değerlendirildi. Böbrek dokusu homojenatlarında malondialdehit (MDA) ve glutatyon (GSH) ölçümü ile lipid peroksidasyonu ve glutatyon seviyesi belirlendi. Bulgular: Kontrol, CAR ve AMI gruplarında %ID/g olarak Tc 99m DMSA uptake’i sırasıyla 29.54±4.72, 29.86±7.47 and 26.37 4.54 olarak hesaplandı. Sisplatin grubunda tüm gruplar içinde en düşük %ID/g, (11.60±3.59) (p<0.01), değeri gözlendi. Sisplatin uygulamasından 30 dakika önce L-karnitin veya amifostin verilmesi sadece sisplatin verilen grupla kıyaslandığında %ID/g’de anlamlı artışa (sırasıyla, 21.28±7.73 ve 18.97±3.24) neden oldu (p<0.002). Sisplatin verilen grupta plazma BUN ve kreatinin düzeylerinde nefrotoksisite ve akut renal yetmezliği gösteren belirgin artışlar gözlendi. MDA ve GSH düzeyleri sisplatinin böbrek dokusunda neden olduğu oksidatif stres ile uyumlu idi. Sonuç: Bulgular L-karnitinin amifostine benzer şekilde sisplatinin neden olduğu nefrotoksisiteyi anlamlı düzeyde azalttığını göstermektedir. (MIRT 2011; 20: 1-6)

Anahtar Kelime:

Konular: Radyoloji, Nükleer Tıp, Tıbbi Görüntüleme

L-Karnitin’in siçanlarda sisplatin nefrotoksisitesine karşı koruyuculuğu: kantitatif böbrek Tc 99m DMSA Uptake’ini kullanarak amifostinle karşılaştırma

Öz:

Objective: In this study, we aimed to investigate the cytoprotective effect of L-carnitine against cisplatin-induced nephrotoxicity and to compare its efficacy with that of amifostin by quantitative renal Tc 99m DMSA uptake. Material and Methods: Male Wistar rats were randomly divided into six groups of six animals each. 1) Control (saline; 5 ml/kg intraperitoneally); 2) L-carnitine (CAR; 300 mg/kg intraperitoneally); 3) Amifostine (AMI; 200 mg /kg intraperitoneally); 4) Cisplatin (CIS;7 mg/kg intraperitoneally); 5) Cisplatin plus L-carnitine (CIS + CAR); 6) Cisplatin plus amifostine (CIS + AMI). L-carnitine and amifostine were injected 30 minutes before cisplatin in Group 5 and 6. Tc 99m DMSA, 7.4 MBq/0.2 ml, was injected through the tail vein 72 hours after the drug administration. Rats were killed and kidneys removed by dissection 2 hours after the injection of the radiopharmaceutical. The percentage of the injected dose per gram of kidney tissue (%ID/g) was calculated. Renal function was monitored by measuring BUN and plasma levels of creatinine. Lipid peroxidation and glutathione content were determined by measuring malondialdehyde (MDA) and reduced glutathione (GSH) in kidney tissue homogenates. Results: Tc 99m DMSA uptake per gram tissue of the kidney as %ID/g was 29.54±4.72, 29.86 ± 7.47 and 26.37 ± 4.54 in the control, CAR and AMI groups respectively. %ID/g was the lowest of all the groups, 11.60±3.59 (p<0.01), in the cisplatin group. Carnitine or amifostine administration 30 minutes before cisplatin injection resulted a significant increase in %ID/g, 21.28±7.73 and 18.97±3.24 respectively, compared to those of cisplatin-treated rats (p<0.002). A marked increase in plasma BUN and creatinine indicating nephrotoxicity and acute renal failure was observed in the cisplatin-treated group. MDA and GSH levels were concordant with cisplatin-induced oxidative stress in the kidney tissue. Conclusion: The results showed that L-carnitine significantly attenuates the cisplatin-induced nephrotoxicity as amifostin. (MIRT 2011; 20: 1-6)

Anahtar Kelime:

Konular: Radyoloji, Nükleer Tıp, Tıbbi Görüntüleme

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 2001;67:93-130.
2. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007;334:115-124.
3. Pabla N, Dong Z. Cisplatin nephrotoxicity:mechanisms and renoprotective strategies.Kidney Int 2008;73:994-1007.
4. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001;24:19-38.
5. Chapela SP, Kriguer N, Fernández E.H, Stella CA. Involvement of L-Carnitine in Cellular Metabolism: Beyond Acyl-CoA Transport. Mini- Reviews in Medicinal Chemistry 2009; 9:1518-1526
6. Martelli E, Caso V. Carnitine protects mitochondria and removes toxic acyls from xenobiotics. Drugs Exp Clin Res 2001;27:27-49.
7. Di Cesare Mannelli L, Ghelardini C, Calvani M, Nicolai R, Mosconi L, Vivoli E, Pacini A, Bartolini A. Protective effect of acetyl- L –carnitine on the apoptotic pathway of peripheral neuropathy. Eur J Neurosci 2007;26:820-827.
8. Di Cesare Mannelli L, Ghelardini C, Calvani M, Nicolai R, Mosconi L, Toscano A, Pacini A, Bartolini A. Neuroprotective effects of acetyl- L -carnitine on neuropathic pain and apoptosis: a role for the nicotinic receptor. J Neurosci Res 2009;87:200-207.
9. Zhu X, Sato EF, Wang Y, Nakamura H, Yodoi J, Inoue M. Acetyl- L -carnitine suppresses apoptosis of thioredoxin 2-deficient DT40 cells. Arch Biochem Biophys 2008;478:154-160.
10. Mahaney Jr FX. Agent designed for war now in doctor’s armamentarium. J Natl Cancer Inst 1990;82:255-257.
11. Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs 2002;13:181-209.
12. Culy CR, Spencer CM. Amifostine: An update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 2001;61:641-684.
13. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A 3rd, von Hoff D, Schuchter LM. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009;27:127-145.
14. Muller-Suur R, Gutsche HU. Tubular reabsorption of technetium-99m DMSA. J Nucl Med 1995; 36:1654-1658.
15. van Luyk, WH, GJ Ensing, DA Piers. Low renal uptake of Tc 99m DMSA in patients with proximal tubular dysfunction. Eur J Nucl Med 1983; 8:404-405.
16. Provoost AP, Van Aken M. Renal handling of technetium-99m DMSA in rats with proximal tubular dysfunction. J Nucl Med 1985;26:1063-1067.
17. Caglar M, Yaris N, Akyuz C. The utility of (99m)Tc-DMSA and Tc(99m) EC scintigraphy for early diagnosis of ifosfamide induced nephrotoxicity. Nucl Med Comm 2001; 22:1325-1332.
18. Anninga JK, Valdes Olmos RA, de Kraker J, van Tinteren H, Hoefnagel CA, van Royen EA. Technetium-99m dimercaptosuccinic acid and ifosfamide tubular dysfunction in children with cancer. Eur J Nucl Med 1994;21:658-662.
19. Zhang JG, Viale M, Esposito M, Lindup WE. Tiopronin protects against the nephrotoxicity of cisplatin in the rat. Hum Exp Toxicol 1999;18:713-717.
20. Yildirim Z, Sogut S, Odaci E, Iraz M, Ozyurt H, Kotuk M, Akyol O. Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. Pharmacol. Res 2003;47:149-156.
21. Wasowicz W, Neve J, Peretz A. Optimized steps in ?uorometric determination of thiobarbituric acid-reactive substances in serum: Importance of extraction pH and in?uence of sample preservation and storage. Clin. Chem 1993;39:2522-2526.
22. Beutler E, Durgun O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med 1963;51:882-888.
23. Chang B, Nishikawa M, Sato E, Utsumi K, Inoue M. L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys 2002;405:55-64.
24. Sayed-Ahmed MM, Eissa MA, Kenawy SA, Mostafa N, Calvani M, Osman AM. Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model. Chemotherapy. 2004;50:162-170.
25. Tufekci O, Gunes D, Ozoğul C, Kolatan E, Altun Z, Yilmaz O, Aktaş S, Erbayraktar Z, Kirkim G, Mutafoğlu K, Soylu A, Serbetçioğlu B, Güneri EA, Olgun N. Evaluation of the effect of acetyl L-carnitine on experimental cisplatin nephrotoxicity. Chemotherapy 2009;55:451-459.
26. Boonsanit D, Kanchanapangka S, Buranakarl C. L-carnitine ameliorates doxorubicin-induced nephrotic syndrome in rats. Nephrology (Carlton) 2006;11:313-320.
27. Al-Majed AA, Sayed-Ahmed MM, Al-Yahya AA, Aleisa AM, Al-Rejaie SS, Al-Shabanah OA. Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model. Pharmacol Res 2006;53:278-286.
28. Pisano C, Pratesi G, Laccabue D, Zunino F, Lo Giudice P, Bellucci A, Pacifici L, Camerini B, Vesci L, Castorina M, Cicuzza S,Tredici G, Marmiroli P, Nicolini G, Galbiati S, Calvani M, Carminati P, Cavaletti G. Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 2003;15;5756-5767.
29. Sayed-Ahmed MM, Salman TM, Gaballah HE, Abou El-Naga SA, Nicolai R, Calvani M. Propionyl-L-carnitine as protector against adriamycin-induced cardiomyopathy. Pharmacol Res 2001;43:513-520.
30. Andrieu-Abadie N, Jaffrezou JP, Hatem S, Laurent G, Levade T, Mercadier JJ. L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation. FASEB J 1999;13:501-510.
31. Luo X, Reichetzer B, Trines J, Benson LN, Lehotay DC. L-carnitine attenuates doxorubicin-induced lipid peroxidation in rats. Free Radic Biol Med 1999;26:1158-1165.
32. Caloglu M, Yurut-Caloglu V, Durmus-Altun G, Oz-Puyan F, Ustun F, Cosar-Alas R, Saynak M, Parlar S, Turan FN, Uzal C. Histopathological and scintigraphic comparisons of the protective effects of L-carnitine and amifostine against radiation-induced late renal toxicity in rats. Clin Exp Pharmacol Physiol 2009;36:523-530.
33. Sernaz Uzunoglu, Hakan Karagol, Fulya Ozpuyan, Rusen Cosar, Irfan Cicin, Vuslat Yurutcaloglu, Bengü Denizli, Özgür Tanriverdi, Necdet Sut and Zafer Kocak. Protective effect of L-carnitine versus amifostine against cisplatin-induced nephrotoxicity in rats. Med Oncol 2010 DOI: 10.1007/s12032-010-9746-2.
34. Vermeulen NP, Baldew GS. The role of lipid peroxidation in the nephrotoxicity of cisplatin. Biochem Pharmacol 1992;44:1193-1199.
35. Nakano S, Gemba M. Potentiation of cisplatin-induced lipid peroxidation in kidney cortical slices by glutathione depletion. Jpn Pharmacol 1989;50:87-92.

APA	YÜREKLİ Y, ÜNAK P, Yenisey Ç, ERTAY T, MÜFTÜLER BİBER F, MEDİNE E (2011). L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake. , 1 - 6.
Chicago	YÜREKLİ Yakup,ÜNAK PERIHAN,Yenisey Çiğdem,ERTAY Türkan,MÜFTÜLER BİBER Fazilet Zümrüt,MEDİNE Emin İlker L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake. (2011): 1 - 6.
MLA	YÜREKLİ Yakup,ÜNAK PERIHAN,Yenisey Çiğdem,ERTAY Türkan,MÜFTÜLER BİBER Fazilet Zümrüt,MEDİNE Emin İlker L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake. , 2011, ss.1 - 6.
AMA	YÜREKLİ Y,ÜNAK P,Yenisey Ç,ERTAY T,MÜFTÜLER BİBER F,MEDİNE E L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake. . 2011; 1 - 6.
Vancouver	YÜREKLİ Y,ÜNAK P,Yenisey Ç,ERTAY T,MÜFTÜLER BİBER F,MEDİNE E L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake. . 2011; 1 - 6.
IEEE	YÜREKLİ Y,ÜNAK P,Yenisey Ç,ERTAY T,MÜFTÜLER BİBER F,MEDİNE E "L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake." , ss.1 - 6, 2011.
ISNAD	YÜREKLİ, Yakup vd. "L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake". (2011), 1-6.

APA	YÜREKLİ Y, ÜNAK P, Yenisey Ç, ERTAY T, MÜFTÜLER BİBER F, MEDİNE E (2011). L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake. Molecular Imaging and Radionuclide Therapy, 20(1), 1 - 6.
Chicago	YÜREKLİ Yakup,ÜNAK PERIHAN,Yenisey Çiğdem,ERTAY Türkan,MÜFTÜLER BİBER Fazilet Zümrüt,MEDİNE Emin İlker L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake. Molecular Imaging and Radionuclide Therapy 20, no.1 (2011): 1 - 6.
MLA	YÜREKLİ Yakup,ÜNAK PERIHAN,Yenisey Çiğdem,ERTAY Türkan,MÜFTÜLER BİBER Fazilet Zümrüt,MEDİNE Emin İlker L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake. Molecular Imaging and Radionuclide Therapy, vol.20, no.1, 2011, ss.1 - 6.
AMA	YÜREKLİ Y,ÜNAK P,Yenisey Ç,ERTAY T,MÜFTÜLER BİBER F,MEDİNE E L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake. Molecular Imaging and Radionuclide Therapy. 2011; 20(1): 1 - 6.
Vancouver	YÜREKLİ Y,ÜNAK P,Yenisey Ç,ERTAY T,MÜFTÜLER BİBER F,MEDİNE E L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake. Molecular Imaging and Radionuclide Therapy. 2011; 20(1): 1 - 6.
IEEE	YÜREKLİ Y,ÜNAK P,Yenisey Ç,ERTAY T,MÜFTÜLER BİBER F,MEDİNE E "L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake." Molecular Imaging and Radionuclide Therapy, 20, ss.1 - 6, 2011.
ISNAD	YÜREKLİ, Yakup vd. "L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake". Molecular Imaging and Radionuclide Therapy 20/1 (2011), 1-6.